RTH258/Brolucizumab

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Neovascular Age Related Macular DegenerationNeovascular Age-Related Macular Degeneration

Phase 3

A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration

CompletedNCT04239027

Novartis PharmaceuticalsNeovascular Age Related Macular Degeneration

Start: 2021-01-26End: 2023-02-02Updated: 2024-10-09

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

CompletedNCT04264819

Novartis PharmaceuticalsNeovascular Age-Related Macular Degeneration

Start: 2020-12-14End: 2023-05-10Updated: 2024-11-07

Related Papers

Disease control, visual and anatomic outcomes at week 48 of brolucizumab treatment in patients with previously suboptimal anatomically controlled neovascular age-related macular degeneration - The SWIFT study.

2025-06-20

Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration.

2023-06-1930 citations